Overview

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945

Status:
Completed
Trial end date:
2018-04-27
Target enrollment:
Participant gender:
Summary
PC945 is a new medicine being developed for treatment of fungal lung diseases. The main purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of PC945
Phase:
Phase 1
Details
Lead Sponsor:
Pulmocide Ltd